November 26, 2025 | Intelligent Commercialisation, artificial intelligence
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

As health and life sciences companies prepare for launch, teams often face the same challenge: data lives in silos. Omnichannel engagement data, field insights, and clinical indicators sit in separate systems – making it difficult to form a connected view of readiness or identify the levers that will most influence launch success.
InConcert™ unites these fragmented datasets to help commercial and medical leaders answer the questions that matter most:
By combining proprietary and client-owned data into one intelligent suite, InConcert™ transforms uncertainty into foresight – helping teams model scenarios, anticipate challenges, and activate strategies with clarity and confidence.
InConcert™ integrates omnichannel, field, and clinical behavior data through an LLM-powered interface that enables intuitive, natural-language querying.
Guided by embedded data scientists and cross-functional experts from across Inizio, users can interrogate their data in real time – moving seamlessly from insight to action.
“InConcert™ helps clients bring their data into focus – turning scattered signals into a clear view of launch readiness,” said Mary-Kate McGarry, Chief Strategy & Innovation Officer, Inizio.
“When teams can see where physicians are most responsive, how field activity drives uptake, and where investment will have the greatest impact, they can make every launch decision with greater insight and confidence.”
At this stage of the lifecycle, success depends on understanding how behavior, communication, and clinical context intersect. InConcert™ combines four core data layers that, together, provide an unparalleled pre-launch vantage point:
Together, these layers create a continuously learning system – one that adapts to each therapy area and market, giving teams a real-time view of where and how to act.
By uniting three critical assets, InConcert™ positions Inizio at the forefront of Intelligent Commercialization™.
Fast to activate and easy to scale, InConcert™ can be deployed within 10–14 weeks, with flexible pilot options that integrate quickly into existing systems and launch workflows.
“Every InConcert™ deployment starts with a client challenge,” said Jamie Avallone, Chief Data Officer, Inizio Evoke.
“Whether it’s identifying high-value targets or validating go-to-market assumptions, InConcert™ gives teams the answers they need – turning complex data into clear, confident launch decisions.”
With more than 700 pharma and biotech partnerships, Inizio helps clients unlock the full potential of their data – transforming fragmented insights into the connected intelligence that drives confident, high-impact launches.
Learn more about InConcert™ or get in touch with one of our experts today.
This content was provided by Inizio
Latest Content from Inizio
Learn how a next-generation approach to field training – powered by GenAI and avatar simulations and enabled through Intelligent Commercialization™ – can transform field force effectiveness by delivering scalable, always-on,...
Inizio, a leading global commercialization partner for pharma and life sciences, today unveiled Inizio Ignite, a reimagined, fully integrated advisory partner designed to accelerate pharma performance through strategy, insights, and innovation.
The MM+M Podcast features a conversation with Jamie Avallone, Chief Data Officer at Inizio Evoke, and Iris Lin, Product Science Lead at Inizio Evoke, who share their perspectives on what...
Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...
Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.
Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.
Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.
As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...
At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...
